Ingrid Adamsons

2.4k total citations
33 papers, 1.8k citations indexed

About

Ingrid Adamsons is a scholar working on Ophthalmology, Public Health, Environmental and Occupational Health and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Ingrid Adamsons has authored 33 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Ophthalmology, 9 papers in Public Health, Environmental and Occupational Health and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Ingrid Adamsons's work include Glaucoma and retinal disorders (23 papers), Retinal Diseases and Treatments (11 papers) and Ocular Surface and Contact Lens (9 papers). Ingrid Adamsons is often cited by papers focused on Glaucoma and retinal disorders (23 papers), Retinal Diseases and Treatments (11 papers) and Ocular Surface and Contact Lens (9 papers). Ingrid Adamsons collaborates with scholars based in United States, Italy and Belgium. Ingrid Adamsons's co-authors include Stefano Miglior, Valter Torri, Norbert Pfeiffer, Thierry Zeyen, José Cunha‐Vaz, Ellen Snyder, Coleen M. Clineschmidt, Kalyan Ghosh, David K. Gieser and Kim M. Strohmaier and has published in prestigious journals such as Diabetes, Ophthalmology and American Journal of Ophthalmology.

In The Last Decade

Ingrid Adamsons

33 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ingrid Adamsons United States	21	1.7k	1.0k	468	218	194	33	1.8k
Hürkan Kerimoğlu Türkiye	15	442 0.3×	328 0.3×	108 0.2×	21 0.1×	78 0.4×	40	651
Molly Harrington United States	13	568 0.3×	378 0.4×	31 0.1×	49 0.2×	215 1.1×	15	936
Naoko Aizawa Japan	19	727 0.4×	523 0.5×	19 0.0×	31 0.1×	105 0.5×	41	900
Haiyun Liu China	15	313 0.2×	250 0.2×	63 0.1×	14 0.1×	95 0.5×	62	593
Seydi Okumuş Türkiye	15	251 0.2×	103 0.1×	38 0.1×	158 0.7×	62 0.3×	44	583
Agnes Boltz Austria	17	757 0.5×	559 0.6×	25 0.1×	11 0.1×	100 0.5×	33	879
Turgay Uçak Türkiye	15	265 0.2×	168 0.2×	48 0.1×	44 0.2×	82 0.4×	33	455
Stefan Palkovits Austria	16	578 0.3×	442 0.4×	25 0.1×	14 0.1×	75 0.4×	50	704
N Fujio Japan	14	655 0.4×	495 0.5×	13 0.0×	13 0.1×	99 0.5×	26	792
Joanna Głogowska-Szeląg Poland	13	141 0.1×	64 0.1×	24 0.1×	34 0.2×	101 0.5×	44	525

Countries citing papers authored by Ingrid Adamsons

Since Specialization

Citations

This map shows the geographic impact of Ingrid Adamsons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingrid Adamsons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingrid Adamsons more than expected).

Fields of papers citing papers by Ingrid Adamsons

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ingrid Adamsons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingrid Adamsons. The network helps show where Ingrid Adamsons may publish in the future.

Co-authorship network of co-authors of Ingrid Adamsons

This figure shows the co-authorship network connecting the top 25 collaborators of Ingrid Adamsons. A scholar is included among the top collaborators of Ingrid Adamsons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ingrid Adamsons. Ingrid Adamsons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pratley, Richard E., Christopher P. Cannon, David Z.I. Cherney, et al.. (2023). Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. The Lancet Healthy Longevity. 4(4). e143–e154. 27 indexed citations

Pratley, Richard E., Samuel Dagogo‐Jack, B Charbonnel, et al.. (2021). 791-P: Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV. Diabetes. 70(Supplement_1). 3 indexed citations

Shedden, Arthur, Ingrid Adamsons, Albert J. Getson, et al.. (2010). Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT™) in patients with elevated intraocular pressure in a randomized clinical trial. Graefe s Archive for Clinical and Experimental Ophthalmology. 248(12). 1757–1764. 35 indexed citations

Fechtner, Robert D., Kathleen McCarroll, Christopher R. Lines, & Ingrid Adamsons. (2005). Efficacy of the Dorzolamide/Timolol Fixed Combination Versus Latanoprost in the Treatment of Ocular Hypertension or Glaucoma: Combined Analysis of Pooled Data from Two Large Randomized Observer and Patient-Masked Studies. Journal of Ocular Pharmacology and Therapeutics. 21(3). 242–249. 14 indexed citations

Trick, Gary L., Ingrid Adamsons, Paul Edwards, et al.. (2005). Dynamic contrast enhanced MRI in patients with diabetic macular edema: initial results. Experimental Eye Research. 81(1). 97–102. 25 indexed citations

Miglior, Stefano, Norbert Pfeiffer, Thierry Zeyen, et al.. (2005). European Glaucoma Prevention Study: Author reply. Ophthalmology. 112(9). 1643–1645. 117 indexed citations

Fechtner, Robert D., et al.. (2003). Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT™) versus latanoprost 0.005% (XALATAN™) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmologica Scandinavica. 82(1). 42–48. 48 indexed citations

Sharpe, Elizabeth, et al.. (1998). Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure. Clinical Therapeutics. 20(3). 454–466. 18 indexed citations

Hutzelmann, Jill, Sally Owens, Arthur Shedden, Ingrid Adamsons, & Enrique Vargas. (1998). Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. British Journal of Ophthalmology. 82(11). 1249–1253. 87 indexed citations

10.

Strohmaier, Kim M., Ellen Snyder, Harvey Dubiner, & Ingrid Adamsons. (1998). The efficacy and safety of the Dorzolamide—timolol combination versus the concomitant administration of its components11Ms. Strohmaier and Drs. Snyder and Adamsons are employees of Merck & Co., Inc, the manufacturer of the dorzolamide-timolol combination. Dr. DuBiner has no proprietary interest in the dorzolamide-timolol combination or Merck.. Ophthalmology. 105(10). 1936–1944. 108 indexed citations

11.

Hutzelmann, Jill, et al.. (1998). A comparison of the efficacy and tolerability of dorzolamide and acetazolamide as adjunctive therapy to timolol. Acta Ophthalmologica Scandinavica. 76(6). 717–722. 19 indexed citations

12.

Adamsons, Ingrid, Coleen M. Clineschmidt, Adam B. Polis, et al.. (1998). The Efficacy and Safety of Dorzolamide as Adjunctive Therapy to Timolol Maleate Gellan Solution in Patients with Elevated Intraocular Pressure. Journal of Glaucoma. 7(4). 247???260–247???260. 19 indexed citations

13.

Adamsons, Ingrid, et al.. (1998). Two-year Safety Study of Dorzolamide as Monotherapy and with Timolol and Pilocarpine. Journal of Glaucoma. 7(6). 395???401–395???401. 21 indexed citations

14.

Ghosh, Kalyan, et al.. (1998). A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide11Ms. Boyle, Dr. Ghosh, and Dr. Adamsons were employees of Merck & Co., Inc, the manufacturer of timolol and dorzolamide, at the time this study was conducted. COSOPT and TRUSOPT are trademark products of Merck & Co., Inc, Whitehouse Station, New Jersey. The other authors have no proprietary interest in timolol, dorzolamide, or Merck.. Ophthalmology. 105(10). 1945–1951. 129 indexed citations

15.

Clineschmidt, Coleen M., et al.. (1998). A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide 11Ms. Clineschmidt, Dr. Adamsons, Dr. Snyder, and Dr. Reines are employees of Merck & Co., Inc., the manufacturer of the dorzolamide-timolol combination. The other authors have no proprietary interest in the dorzolamide-timolol combination or in Merck.. Ophthalmology. 105(10). 1952–1959. 120 indexed citations

16.

Adamsons, Ingrid. (1996). The Association of Postoperative Subjective Visual Function With Acuity, Glare, and Contrast Sensitivity in Patients With Early Cataract. Archives of Ophthalmology. 114(5). 529–529. 37 indexed citations

17.

Adamsons, Ingrid, et al.. (1992). CORRELATION OF VISUAL IMPAIRMENT QUESTIONNAIRE RESULTS WITH GLARE AND CONTRAST TEST-RESULTS IN CATARACT PATIENTS. UCL Discovery (University College London). 1 indexed citations

18.

Adamsons, Ingrid. (1992). The Effect of Early Cataracts on Glare and Contrast Sensitivity. Archives of Ophthalmology. 110(8). 1081–1081. 72 indexed citations

19.

Adamsons, Ingrid, et al.. (1991). A New Method for Documenting Lens Opacities. American Journal of Ophthalmology. 111(1). 65–70. 24 indexed citations

20.

Adamsons, Ingrid & Hugh R. Taylor. (1990). Major causes of world blindness: their treatment and prevention. Current Opinion in Ophthalmology. 1(6). 635–642. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact